NEXT™ CAR-T In Vivo Animal Testing Services
Creative Biolabs provides a comprehensive suite of in vivo solutions designed to bridge the gap between initial genetic engineering and successful human application. We specialize in evaluating sophisticated modalities such as logic-gated CARs, armored CARs secreting pro-inflammatory cytokines, and lipid nanoparticle (LNP)-mediated in vivo reprogramming. Our testing framework ensures that your candidate achieves optimal biodistribution, avoids "off-tumor" toxicity, and maintains long-term persistence within an immunosuppressive tumor microenvironment (TME). By leveraging high-fidelity models, we help you mitigate the risks associated with antigen escape and T-cell exhaustion early in the development cycle.
Introduction of Next CAR-T In Vivo Animal Testing
The evolution of CAR-T therapy from simple CD19 targeting to "programmable immunity" requires sophisticated in vivo validation that standard models cannot provide. Recent scientific breakthroughs emphasize that ex vivo data are insufficient for predicting the complex interactions of the tumor microenvironment or the risks of in vivo engineering via viral or non-viral vectors. Research indicates that the transition to direct in vivo generation offers a new era of therapeutic scalability, but it raises critical questions regarding specificity and genomic safety. Creative Biolabs integrates these latest developments, including vaccine-boosted restimulation and 3Rs-compliant NAMs, to provide a holistic view of therapeutic potential, ensuring your CAR-T candidate is both potent and safety-optimized for the clinic.
In Vivo Animal Testing for Cellular and Gene Therapy
CAR-T Animal Model >
To provide a wide range of models such as syngeneic models, humanized models, PDX models, CDX models …
CAR-T In Vivo Pharmacology >
To provide pre-clinical pharmacological services for scientific consideration of a Next CAR-T product’s properties and its predictive clinical use …
Viability and Biodistribution Studies >
To elucidate in vivo routes of action, dosing regimens, dose response and utility, and duration of action …
Cytokine Release Syndrome Evaluation >
To evaluate the CRS based on the revised severity rating system and try to predict new effective biomarkers for CRS …
Pathology & Histology Evaluation >
A full range of clinical pathology laboratory services to support drug discovery, regulatory requirements …
CAR-T In Vivo Toxicology >
To evaluate potential safety risks in animal models and predict potential safety risks for humans prior to human exposure via body weight …
In Vivo Efficacy >
We offer a wide range of studies and various endpoints to evaluate the anti-tumor efficacy of cellular and gene therapeutic products …
Quality Control >
To implement strict inspections and validations on each and every step that conform to the GLP (FDA/OECD) regulations …
Ready to validate your Next-Gen CAR-T construct? Consult with our PhD-level immunologists to design your definitive in vivo study.
Workflow
To ensure scientific rigor and project alignment, our workflow is structured to be transparent and data-driven, providing a clear roadmap from material submission to regulatory-grade reporting.
Publication
This paper presents a general pipeline using directed evolution to discover peptide mimotopes that can be used to create amphiphile vaccines (amph-mimotopes) for boosting any CAR-T cell. Applying this to the clinically used CD19 CAR (FMC63), they generated a high-affinity mimotope that, when administered as a vaccine, potently stimulated CAR-T expansion, enhanced memory differentiation, and improved leukemia clearance in multiple mouse models without the toxicity seen with higher-affinity ligands.
Fig.1 Amph-mimotope peptide-pulsed DCs enhance the anti-leukaemic activity of CD19 CAR-T cells. 1
Why Choose Us
Creative Biolabs stands at the intersection of classical immunology and cutting-edge genetic engineering, providing a unique infrastructure for Next-Gen CAR-T validation. Our advantages include:
Pioneering Dual-Platform Methodology
We offer both gold-standard humanized rodent models and rapid, 3Rs-compliant chicken CAM assays. This allows for high-throughput efficacy screening of multiple constructs in ten days before advancing lead candidates to complex murine models for validation.
Specialized In Vivo Engineering Support
Our facility is uniquely equipped for programmable immunity. We provide pharmacokinetic and biodistribution tracking for non-viral LNP and viral vector systems, ensuring high-fidelity T-cell transduction and minimal off-target sequestration in metabolic organs during development.
Advanced Multi-Species Safety Profiling
Beyond standard efficacy, we provide deep-dive toxicity assessments, including LNP-associated hepatic injury and ICANS evaluation. Integrating Sprague-Dawley rats and large animal pilots ensures a robust safety dataset that traditional mouse-only studies often lack entirely.
Unmatched Translational Accuracy Benchmarks
We utilize high-fidelity patient-derived xenografts (PDX) preserving original tumor architecture. Published data confirm our models provide superior predictive value for clinical success, effectively replicating the immunosuppressive barriers found in complex solid tumor microenvironments.
Don't leave your regulatory success to chance. Experience the Creative Biolabs advantage—Contact us for a detailed quote and data-sharing session.
FAQs
Can you model CAR-T testing for solid tumors?
Yes. Creative Biolabs utilizes PDX and orthotopic models that replicate the physical barriers, tumor stroma, and immunosuppressive microenvironment of solid cancers.
What is the advantage of the chicken CAM assay?
The CAM assay serves as a rapid "filter," providing results in under 10 days. It is ideal for screening multiple construct variations for anti-tumor efficacy and anti-angiogenic properties before selecting a lead for mouse studies.
Do you support in vivo engineering (LNP/viral) projects?
Certainly. We provide specialized biodistribution and genomic integration assays to track the transduction efficiency and long-term safety of CAR-T generation occurring directly within the host.
Customer Review
-
Unparalleled Persistence Tracking
Using Creative Biolabs' testing in our research has significantly facilitated our understanding of T-cell exhaustion markers. Their flow cytometry panels for Tscm phenotyping provided the definitive proof of durable memory we needed for our internal stakeholders. - Dr. Al*** M -
Expertise in In Vivo Reprogramming
The LNP biodistribution studies were handled with extreme precision. Creative Biolabs helped us identify unexpected liver sequestration of our vectors, allowing us to re-engineer our targeting ligands before reaching the costly NHP stage. - Michael R***s
Related Services
TCR-T and CAR-T NK MA Cell GLP Production
Creative Biolabs provides a GLP production platform for CAR-T/NK/MA therapies. We offer aseptic culture, genetic engineering, and stringent QC to ensure the purity, safety, and potency of your therapeutic products.
Learn More →Regulatory T Cell Therapy Development Services
Creative Biolabs develops CAR-Treg therapies via subpopulation profiling, migration assays, and suppression testing. We optimize antigen specificity and functional survival to treat autoimmune disorders and promote immune tolerance.
Learn More →Contact Us
Creative Biolabs is dedicated to transforming the promise of next-generation CAR-T therapies into clinical reality. Our integrated in vivo testing platform provides the precision, speed, and regulatory rigor required for the modern immuno-oncology landscape.
Inquire Now for a Confidential Project Discussion and Comprehensive Quotation
Reference
- Grzywa, Tomasz M., et al. "Directed evolution-based discovery of ligands for in vivo restimulation of chimeric antigen receptor T cells." Nature Biomedical Engineering (2025): 1-21. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.1038/s41551-025-01470-0
Download our brochure